Zealand Pharma A/S (CPH: ZEAL)
Market Cap | 62.88B |
Revenue (ttm) | 367.97M |
Net Income (ttm) | -712.00M |
Shares Out | 70.94M |
EPS (ttm) | -11.82 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,155,592 |
Open | 871.50 |
Previous Close | 871.50 |
Day's Range | 871.50 - 901.50 |
52-Week Range | 252.60 - 972.00 |
Beta | 0.64 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 7, 2024 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III... [Read more]
Financial Performance
In 2023, Zealand Pharma's revenue was 342.79 million, an increase of 229.65% compared to the previous year's 103.99 million. Losses were -703.74 million, -41.46% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/i/b/press7-2618863.jpg)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...
![](https://cdn.snapi.dev/images/v1/g/f/gfre2w-2609274.jpg)
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders ...
![](https://cdn.snapi.dev/images/v1/i/6/press7-2604744.jpg)
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 22, 2024 – Zealand Pharma A/S (“Zealand”) ...
![](https://cdn.benzinga.com/files/images/story/2024/08/22/globe-chart-shutter.jpeg?optimize=medium&dpr=1&auto=jpg&height=480&width=720&fit=crop)
International Small-Cap ETF Reaches 52-Week High, Leaving Investors Wondering What's Next
The iShares MSCI EAFE Small-Cap ETF (NASDAQ: SCZ) is making headlines, hitting a fresh 52-week high of $65.60 during day trading on Wednesday. This milestone caps a positive year for the ETF, which h...
Zealand Pharma reports 1H results
Zealand Pharma reports 1H results
![](https://cdn.snapi.dev/images/v1/e/z/press2-2594200.jpg)
Zealand Pharma major shareholder announcement: Bank of America Corporation
Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CV...
![](https://www.reuters.com/resizer/v2/466BJJQ7PVGY5O53NZ3KL65MHM.png?auth=b9c3bf166c40a6778eb5672993fde7c30a15f48329026674eff92afd8da1d0ca&height=1005&width=1920&quality=80&smart=true)
Zealand Pharma seeks big pharma partners for obesity drug candidate
Denmark's Zealand Pharma is set to start talks in the second half of this year with other pharmaceutical companies for potential partnerships to develop and commercialize its weight-loss drug petrelin...
![](https://cdn.snapi.dev/images/v1/e/a/press6-2590659.jpg)
Zealand Pharma Announces Financial Results for the First Half of 2024
Company announcement - No. 39 / 2024 Zealand Pharma Announces Financial Results for the First Half of 2024 Very strong progress across R&D pipeline followed by substantial capital raise enabling furth...
![](https://cdn.snapi.dev/images/v1/h/a/conf13-2584067.jpg)
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nas...
![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536)
Zealand Pharma: A Bit Frothy
Zealand Pharma's stock surged 125% YTD on positive trial data, but limited commercial potential may warrant caution for investors.
![](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536)
Zealand Pharma: A Bit Frothy
Zealand Pharma's stock surged 125% YTD on positive trial data, but limited commercial potential may warrant caution for investors.
![](https://cdn.snapi.dev/images/v1/i/b/press1-2551674.jpg)
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
Press release – 7 / 2024 Zealand Pharma Appoints Eric Cox as Chief Commercial Officer Copenhagen, Denmark, 29 July 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnolo...
![](https://cdn.snapi.dev/images/v1/n/n/press18-2502267.jpg)
Zealand Pharma major shareholder announcement: Van Herk Investments
Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.
![](https://cdn.snapi.dev/images/v1/v/g/press7-2501283.jpg)
Zealand Pharma completes registration of capital increase
Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA,...
![](https://cdn.snapi.dev/images/v1/m/5/press8-2496449.jpg)
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT F...
![](https://cdn.snapi.dev/images/v1/l/e/press19-2496066.jpg)
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion N...
![](https://cdn.snapi.dev/images/v1/l/m/press6-2495539.jpg)
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR D...
![](https://cdn.snapi.dev/images/v1/t/v/zealand-pharma-shares-jump-17--2490314.jpg)
Zealand Pharma Shares Jump 17% After Positive Trial Results For Ozempic Competitor
Shares for Zealand Pharma rose by over 17% on Friday, after the Danish biotech firm announced positive trial results for petrelintide, a new weight loss drug the company said could compete against Nov...
![](https://cdn.snapi.dev/images/v1/y/2/biotech9-2490144.jpg)
Zealand Pharma stock rallies 20%: what happened?
Zealand Pharma (CPH: ZEAL) rallied more than 20% this morning after reporting positive results from an early stage trial of its new weight loss treatment. The biotech firm is now trading at an all-ti...
![](https://cdn.snapi.dev/images/v1/4/c/biotech34-2489683.jpg)
Weight loss drug contender Zealand Pharma jumps 23% on trial results
Zealand Pharma shares popped on Friday on positive weight loss results from long-acting amylin analog petrelintide. The company said petrelintide may produce similar weight loss results and a "better ...
![](https://cdn.snapi.dev/images/v1/c/y/biotech32-2489598.jpg)
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drug...
![](https://cdn.snapi.dev/images/v1/y/g/biotech13-2488563.jpg)
Zealand Pharma's drug reduces weight by 8.6% in early-stage study
Zealand Pharma said on Thursday an early-stage study showed a high dose of its drug helped reduce weight by an average 8.6% after 16 weekly doses.
![](https://cdn.snapi.dev/images/v1/q/i/press12-2488537.jpg)
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Body...
![](https://cdn.snapi.dev/images/v1/w/w/wwfk2-2483102.jpg)
New Weight-Loss Drugs and Devices Are Coming This Week
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.